Enseval Putera Megatrading Tbk PTEPMT:JKT

3,100
0.00 / 0.00%
306.80k
13.41 %
0.2977
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 25 2015 09:49 BST.

About the company

17.10tn520.22bn19895.67k
Revenue in IDR (TTM)Net income in IDRIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
Enseval Putera Megatrading Tbk PT
Jl. Pulo Lentut No. 10
Kawasan Industri Pulo Gadung
JAKARTA13920
Indonesia
IDN
Phone+62 2 146822422Fax+62 214609039Websitehttp://www.enseval.com
PT Enseval Putera Megatrading Tbk is an Indonesia-based company primarily engaged in distributing and trading pharmaceutical and consumer products. Its business is classified into three operating segments: pharmaceutical products, consumer products and others. The pharmaceutical products segment includes the distribution of prescription drugs and over-the-counter (OTC) drugs, while the consumer products segment comprises the distribution of nutritional products and other consumer products. Its others segment includes the distribution of medical equipment, veterinary products and raw materials for pharmaceutical industry as well as the provision of health care services. Its subsidiaries include PT Tri Sapta Jaya, which distributes pharmaceutical and health care products; PT Millenia Dharma Insani, which operates clinics under the brand name of Mitrasarana, and PT Enseval Medika Prima, which distributes medical equipment.

Mergers & acquisitions

There are no recent mergers or acquisitions for Enseval Putera Megatrading Tbk PT.
Data delayed at least 15 minutes, as of May 25 2015 09:49 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Mayne Pharma Group Ltd
1.36tn173.80bn9.44tn16042.863.9434.276.930.02720.02720.21270.29530.45813.434.43--5.856.756.936.7551.7048.2712.768.070.9427--0.317515.3171.70219.54848.86--422.93--
QIANJIANG YONGAN PHARMACEUTICAL CO.,LTD.
1.40tn76.11bn8.53tn883112.093.62--6.100.19240.19243.545.960.56215.289.64748,8713.064.783.194.7815.9520.695.4410.309.05--0.00--25.9616.2437.88-13.37921.97--
Shanghai Hile Bio-Technology Co Ltd
588.28bn208.51bn9.36tn--33.687.55--15.920.46950.46951.322.09----------------77.64--34.65--2.04--0.00---10.5149---14.7893------
Lotus Pharmaceutical Co Ltd
1.35tn-134.86bn8.20tn953--2.45--6.07-1.2525-1.252514.7232.670.30762.062.493,279,485-3.9987-8.3002-5.7575-8.300253.4655.14-12.9991-14.19141.42-3.13790.3257--10.4130.65-210.1209--53.52--
TaiGen Biopharmaceuticals Holdings Ltd
32.43bn-184.82bn9.48tn77--28.54--292.38-0.614-0.6140.10771.100.0612--13.14---34.8772---39.1279--76.35---569.9044------0.00--49.69--6.59------
SanBio Co Ltd
350.34bn188.37bn9.03tn1342.21--47.7925.7844.5444.5482.11-2.2033------248,400,800------------53.77----117.781.08--1,480.73--394.55------
iNtRON Biotechnology Inc
119.86bn246.58m8.20tn8136,717.4535.11820.4468.381.331.33714.961,391.380.34656.703.38--0.07130.14090.07940.140955.4051.800.20570.265417.410.92360.4090.007.594.96-94.195-55.71655.15--
Genexine Inc
200.03bn-89.03bn8.25tn103--6.59616.1741.24-1,001.177-1,001.1772,341.1813,678.010.19626.455.56---8.7236-12.9876-10.0884-12.987679.6579.85-44.509-93.41987.07-1.69130.0671--189.4373.1817.62--37.12--
Amicogen Inc
328.25bn90.83bn8.51tn10693.7614.2482.5325.91877.73877.733,172.755,779.580.55376.342.65257,845,70015.22--16.38--51.18--27.49--6.8982.900.0016--17.91---0.1543------
Daewoong Co., Ltd.
10.74tn285.97bn8.80tn28322.541.2510.760.81952,794.432,794.43104,91350,508.960.93653.447.96--3.97--7.09--40.07--4.24--2.94--0.1909--6.00---41.5987------
Ilyang Pharmaceutical Co., Ltd
2.35tn-110.40bn8.93tn630--4.2213.073.80-540.3408-540.340811,503.459,724.270.47793.022.24331,137,300-1.19361.45-1.94771.4542.2641.04-2.49791.850.72690.64420.51943.95--5.21----7.90--
Dong-A Socio Holdings Co Ltd
7.57tn20.61bn8.94tn341778.151.5026.291.18211.40211.40141,394109,5900.60953.817.76--0.62685.241.115.2430.3742.791.036.350.54385.800.440221.9810.47-6.1515-67.0063-51.3963.75-15.2694
Chabiotech Co Ltd
4.15tn-56.70bn9.25tn122--2.5338.882.23-96.5662-95.60666,814.416,051.720.528725.365.59--0.37722.670.59022.6715.2115.810.71352.433.51--0.051---10.7255-0.7898-141.747--18.30--
Enseval Putera Megatrading Tbk PT
17.10tn520.22bn8.40tn5.67k16.142.3013.220.4909192.06192.066,314.561,346.22.867.688.383,017,621,0008.6915.7015.1115.7011.4511.173.042.991.26--0.0418--8.8914.759.979.1813.98-28.7116
Industri Jamu dan Farmasi Sd Mncl Tbk PT
2.19tn417.31bn8.70tn4.42k20.853.1618.173.9827.8227.82145.82183.510.74754.777.16494,527,70014.26--15.18--38.32--19.08--10.74--0.00---7.3537--2.28------
Tempo Scan Pacific Tbk PT
7.51tn579.38bn9.18tn6.00k15.842.2512.921.22128.75128.751,669.36908.171.374.479.111,252,019,00010.6217.3714.0317.3738.8738.197.789.212.15--0.0223--9.5910.80-8.70499.9926.51--
Data as of May 25 2015. Currency figures normalised to Enseval Putera Megatrading Tbk PT's reporting currency: Indonesian Rupiah IDR.
Data delayed at least 20 minutes, as of May 25 2015 17:48 BST.

Institutional shareholders

HolderShares% Held
Manulife Asset Management Services Bhd.
as of 30 Apr 2014
505.50k0.02%
0.02%
Per cent of shares
held by top holders
Data from 30 Apr 2014 - 30 Apr 2014Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.